Qiming Venture Partners and Founding Managing Partner Duane Kuang Named to Touzijia 2025 China Fund Partners Annual List
The list aims to recognize investment institutions and individual investors who have demonstrated sustained commitment and achieved outstanding results in the equity investment industry over the past year, collectively bearing witness to the industry's moments of glory.
Recently, Touzijia's 2025 China Fund Partners Annual Rankings were officially released. The rankings aim to honor investment institutions and investors who have made sustained contributions and achieved outstanding results in the equity investment industry over the past year, collectively witnessing the industry's moments of glory.
The annual rankings consist of institutional and individual categories. Qiming Venture Partners and Duane Kuang, Founding Managing Partner of Qiming Venture Partners, were both selected.
Qiming Venture Partners
Selected for:
- Top 50 Best Venture Capital Institutions of the Year
- Top 20 Most LP-Favored Investment Institutions of the Year
Duane Kuang, Founding Managing Partner of Qiming Venture Partners
Selected for:
- Top 25 Best Venture Capital Investors of the Year
Touzijia noted that China's equity investment industry has reached a new starting point in 2025. On the investment side, VC/PE firms operating in China are increasingly concentrating on early-stage investments, favoring strategies of "investing early and investing small." On the exit side, overseas IPO markets gradually recovered in 2024, while Hong Kong listings and the STAR Market have become mainstream channels; entering 2025, the IPO market has become even more active, with M&A and restructuring also surging.
Source | Touzijia
Past Highlights
Qiming Honors | Qiming Venture Partners and Founding Managing Partner Duane Kuang Selected for Touzijia's 2024 Fund Partners Annual Rankings Qiming Stars | 7 Qiming Venture Partners Portfolio Companies Selected for QbitAI Think Tank's 2025H1 AI 100 Product Rankings Qiming Honors | Qiming Venture Partners and Portfolio Companies Win Multiple Awards at the 9th Annual Healthcare Investment Excellence Awards
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns in their respective industries.
Many companies in Qiming Venture Partners' portfolio have grown into the most influential players in their fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.